Temperature-Controlled Solutions Are Supporting The Future Of Pharma And Biopharma

When the COVID-19 pandemic threatened to entirely disrupt the execution of clinical trials, decentralized clinical trials (DCT) and direct-to-patient (DTP) models were quickly adopted as a solution. While these logistics are incredibly complex, the pandemic has shown the industry that it remains possible to continue trials while maintaining their integrity and the safety of both materials and patients. Subsequently, the industry’s adoption of these models has been particularly accelerated.

Direct-to/from-patient models are proving to increase patient convenience and engagement — thereby potentially ushering life-saving therapies to market faster. Where previously, certain patients had no chance to participate in trials that required them to leave their homes, the direct-to-patient model offers hope to all with chronic or rare diseases. Similarly, decentralization of clinical trials also opens possibilities for large scale global scope, reaching patients even in remote locales.

With the global markets for both decentralized clinical trials and next-generation medicines growing, the need for expert global logistics management is also rising. The storage and shipment of biological materials requires special handling and a secure temperature-controlled supply chain. It is essential that clinical trials materials reach patients and biological samples reach labs in a timely manner, meeting precise study requirements.